RxDoctor Payments Data

Elizabeth Riccardi, MD

Internal Medicine · Syracuse, NYNPI 1619294279

Payments from drug & device makers

$406in general payments, 2019–2025

Across 31 payments — averaging $13.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$140
  • Pfizer$52
  • Astellas Pharma US Inc$49
  • GSK$45
  • Sanofi-aventis U.S. LLC$37
  • Boehringer Ingelheim$30
  • plus $53 from 4 others

What the payments were for

  • Food & beverage$406100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$406 in reported general payments places this provider in the 60th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$73,331
Medicare patients
172
Services billed
925

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide105$100,394
JardianceEmpagliflozin92$66,513
EliquisApixaban32$48,525
TrulicityDulaglutide22$31,567
Trelegy ElliptaFluticasone/Umeclidin/Vilanter44$31,117
Tresiba Flextouch U-200Insulin Degludec21$17,968
InvokanaCanagliflozin18$16,725
XareltoRivaroxaban15$13,801
Tiotropium Bromide11$12,419
Incruse ElliptaUmeclidinium Bromide26$9,757
AmbienZolpidem Tartrate12$7,212
Fluticasone-SalmeterolFluticasone Propion/Salmeterol21$6,009
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog14$4,424
Lantus SolostarInsulin Glargine,hum.Rec.Anlog24$4,359
Levothyroxine Sodium345$3,920

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$140$100,394105 claims
Boehringer IngelheimJardiance$30$66,51392 claims
PfizerEliquis$52$48,52532 claims
GSKTrelegy Ellipta, Incruse Ellipta$45$40,87470 claims
Sanofi-aventis U.S. LLCAmbien$37$7,21212 claims
AbbVieSynthroid$16$1,77337 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in Syracuse

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →